News
TLPH
0.9900
-1.98%
-0.0200
Weekly Report: what happened at TLPH last week (0826-0830)?
Weekly Report · 5d ago
Weekly Report: what happened at TLPH last week (0819-0823)?
Weekly Report · 08/26 12:16
TALPHERA ANNOUNCES FIRST PATIENT ENROLLED IN THE REGISTRATIONAL TRIAL EVALUATING NAFAMOSTAT FOR ANTICOAGULATION OF THE EXTRACORPOREAL CIRCUIT
Reuters · 08/19 12:30
Weekly Report: what happened at TLPH last week (0812-0816)?
Weekly Report · 08/19 11:57
Bullish Outlook on Talphera’s Niyad: Phase 3 Trial Advancements and Market Potential Justify Buy Rating
TipRanks · 08/16 11:25
Buy Rating Affirmed for Talphera Amid Strategic Advancements in NEPHRO CRRT Study
TipRanks · 08/15 15:35
TALPHERA INC <TLPH.O>: ALLIANCE GLOBAL PARTNERS CUTS TARGET PRICE TO $3.50 FROM $4.25
Reuters · 08/15 11:13
U.S. RESEARCH ROUNDUP-Allstate, bluebird bio , Vicinity Motor
Reuters · 08/15 06:57
Talphera Inc reports results for the quarter ended in January - Earnings Summary
Reuters · 08/15 04:08
TLPH Stock Earnings: Talphera Beats EPS for Q2 2024
Investorplace · 08/15 00:55
Talphera Announces CMO Retirement and Successor Appointment
TipRanks · 08/14 20:43
AcelRx Pharmaceuticals GAAP EPS of -$0.15 beats by $0.06
Seeking Alpha · 08/14 20:37
Talphera Q2 EPS $(0.15) Beats $(0.23) Estimate
Benzinga · 08/14 20:08
TALPHERA ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Reuters · 08/14 20:01
Talphera: Q2 Earnings Snapshot
Barchart · 08/14 15:06
Weekly Report: what happened at TLPH last week (0805-0809)?
Weekly Report · 08/12 12:01
Weekly Report: what happened at TLPH last week (0729-0802)?
Weekly Report · 08/05 12:15
Weekly Report: what happened at TLPH last week (0722-0726)?
Weekly Report · 07/29 12:01
Weekly Report: what happened at TLPH last week (0715-0719)?
Weekly Report · 07/22 12:02
Weekly Report: what happened at TLPH last week (0708-0712)?
Weekly Report · 07/15 11:58
More
Webull provides a variety of real-time TLPH stock news. You can receive the latest news about Talphera Inc through multiple platforms. This information may help you make smarter investment decisions.
About TLPH
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is its nafamostat formulation for direct intravenous (IV) infusion being explored as an investigational product for the antiviral treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. Its pre-filled syringe product candidates include Fedsyra and Phenylephrine.